HEADACHE/MIGRAINE

The monoclonal antibody against CGRP reduced the frequency of episodic cluster headache attacks significantly more than placebo, though the Eli Lilly therapy failed to separate from placebo in the disease’s chronic presentation.
The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern discussed the need to better coordinate care between providers when telemedicine is being utilized in headache and migraine care.

SAP Partner Banner

About NeurologyLive's Headache & Migraine Clinical Focus page:

The NeurologyLive Headache & Migraine Clinical Focus page serves as a hub for breaking news, videos, and other resources. Items covered here include updates from the most-attended neurological conferences and annual meetings via articles and video interviews with neurology’s leading experts and key opinion leaders.
 
This page will always be up-to-date, providing breaking news coverage of U.S. Food and Drug Administration (FDA) approvals, key takeaways from the latest clinical trials, and notifications of recent updates to clinical guidelines for headaches and migraines. Additionally, this Clinical Focus page provides an array of condition-specific resources, like information on new and emerging therapies for migraine relief and prevention.